Last reviewed · How we verify
Anticancer therapy 3
At a glance
| Generic name | Anticancer therapy 3 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticancer therapy 3 CI brief — competitive landscape report
- Anticancer therapy 3 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI